Get started
AMGEN INC. DL-,0001AA

AMGEN INC. DL-,0001

297.20EURD
−0.80−0.27%
As of today at 09:34 GMT
EUR
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Forecast Seasonals Bonds

AMG fundamentals

Key facts

Market capitalization‪161.14 B‬EUR
Dividend yield (indicated)2.93%
Price to earnings Ratio (TTM)42.77
Basic EPS (TTM)7.36EUR
Founded1980
Employees (FY)‪28 K‬
CEORobert A. Bradway
Websiteamgen.com
About

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Ownership
‪‪537.21 M‬‬
Free Float shares
‪‪536.10 M‬‬ (99.79%)
Closely held shares
‪‪1.10 M‬‬ (0.21%)
Free Float shares
‪‪536.10 M‬‬ (99.79%)
Closely held shares
‪‪1.10 M‬‬ (0.21%)
Capital structure
Market cap
‪‪161.14 B‬‬
Debt
‪‪58.81 B‬‬
Cash & equivalents
‪‪11.57 B‬‬
Enterprise value
‪‪208.38 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪161.14 B‬‬
Price to earning ratio (P/E)
42.77x
Price to sales ratio (P/S)
5.26x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
42.77x
Price to sales ratio (P/S)
5.26x
Valuation ratios
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪15.00‬
‪30.00‬
‪45.00‬
‪60.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−12%‬
‪0%‬
‪12%‬
‪24%‬
‪36%‬
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪‪−3.00 B‬‬
‪0.00‬
‪‪3.00 B‬‬
‪‪6.00 B‬‬
‪‪9.00 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2024
Human Therapeutics
Other
By country
Period: 2024
United States
Rest of World
Canada

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪‪2.50 B‬‬
‪‪5.00 B‬‬
‪‪7.50 B‬‬
‪‪10.00 B‬‬
Actual
Estimate
Earnings
Next:Apr 23, 2025
Q1 '24
Q2 '24
Q3 '24
Q4 '24
Q1 '25
‪0.00‬
‪1.50‬
‪3.00‬
‪4.50‬
‪6.00‬
Actual
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
119.26%
Payout ratio (TTM)
Dividend yield TTM
2.81%
Next payment
2.198
Next ex-date
May 16, 2025
Dividend history
‪2.50%‬
‪2.75%‬
‪3.00%‬
‪3.25%‬
‪3.50%‬
2020
2021
2022
2023
2024
‪0.00‬
‪2.50‬
‪5.00‬
‪7.50‬
‪10.00‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
‪0.00‬
‪‪15.00 B‬‬
‪‪30.00 B‬‬
‪‪45.00 B‬‬
‪‪60.00 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
‪0.00‬
‪‪16.00 B‬‬
‪‪32.00 B‬‬
‪‪48.00 B‬‬
‪‪64.00 B‬‬
Assets
Liabilities